References
- Andersen, C.Y., & Ezcurra, D. (2014). Human steroidogenesis: implications for controlled ovarian stimulation with exogenous gonadotropins. Reproductive Biology and Endocrinology, 12, 128. doi: https://doi.org/10.1186/1477-7827-12-128.
- Anderson, R.A., & Wallace, W.H. (2011). Fertility preservation in girls and young women. Clinical Endocrinology, 75, 409–419. doi: https://doi.org/10.1111/j.1365-2265.2011.04100.x.
- Azim, A.A., Costantini-Ferrando, M., & Oktay, K. (2008). Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. Journal of Clinical Oncology, 26, 2630–2635. doi: https://doi.org/10.1200/JCO.2007.14.8700.
- Baerwald, A.R., Adams, G.P., & Pierson, R.A. (2003). Characterization of ovarian follicular wave dynamics in women. Biology of Reproduction, 69, 1023–1031. doi: https://doi.org/10.1095/biolreprod.103.017772.
- Baerwald, A.R., Adams, G.P., & Pierson, R.A. (2012). Ovarian antral folliculogenesis during the human menstrual cycle: a review. Human Reproduction Update, 18, 73–91. doi: https://doi.org/10.1093/humupd/dmr039.
- Cakmak, H., & Rosen, M.P. (2013). Ovarian stimulation in cancer patients. Fertility and Sterility, 99, 1476–1484. doi: https://doi.org/10.1016/j.fertnstert.2013.03.029.
- Cakmak, H., & Rosen, M.P. (2015). Random-start ovarian stimulation in patients with cancer. Current Opinion in Obstetrics and Gynecology, 27, 215–221. doi: https://doi.org/10.1097/GCO.0000000000000180.
- Checa, M.A., Brassesco, M., Sastre, M., Gomez, M., Herrero, J., Marque, L., … Espinos, J.J. (2015). Random-start GnRH antagonist for emergency fertility preservation: a self-controlled trial. International Journal of Womens Health, 7, 219–225. doi: 10.2147/IJWH.S66743.
- Chen, H., Wang, Y., Lyu, Q., Ai, A., Fu, Y., Tian, H., … Kuang, Y. (2015). Comparison of live-birth defects after luteal-phase ovarian stimulation vs. conventional ovarian stimulation for in vitro fertilization and vitrified embryo transfer cycles. Fertility and Sterility, 103, 1194–1201.e2. doi: https://doi.org/10.1016/j.fertnstert.2015.02.020.
- Chian, R.C., Huang, J.Y., Gilbert, L., Son, W.Y., Holzer, H., Cui, S.J., … Tan, S.L. (2009). Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertility and Sterility, 91, 2391–2398. doi: https://doi.org/10.1016/j.fertnstert.2008.04.014.
- Cobo, A., & Diaz, C. (2011). Clinical application of oocyte vitrification: a systematic review and meta-analysis of randomized controlled trials. Fertility and Sterility, 96, 277–285. doi: https://doi.org/10.1016/j.fertnstert.2011.06.030.
- Cobo, A., Garrido, N., Coello, A., Castello, D., Pellicer, A., & Remohi, J. (2014a). Cumulative live birth rates (CLBR) according to the number of vitrified oocytes consumed in an ovum donation (OD)/egg-banking program. Human Reproduction, 29(Suppl. 1), i108. doi: https://doi.org/10.1093/humrep/29.Supplement_1.1.
- Cobo, A., Garrido, N., Pellicer, A., & Remohi, J. (2015). Six years’ experience in ovum donation using vitrified oocytes: report of cumulative outcomes, impact of storage time, and development of a predictive model for oocyte survival rate. Fertility and Sterility, 104, 1426–1434.e1-8. doi: https://doi.org/10.1016/j.fertnstert.2015.08.020.
- Cobo, A., Serra, V., Garrido, N., Olmo, I., Pellicer, A., & Remohi, J. (2014b). Obstetric and perinatal outcome of babies born from vitrified oocytes. Fertility and Sterility, 102, 1006–1015.e4. doi: https://doi.org/10.1016/j.fertnstert.2014.06.019.
- Ethics Committee of the American Society for Reproductive Medicine. (2013). Fertility preservation and reproduction in patients facing gonadotoxic therapies: a committee opinion. Fertility and Sterility, 100, 1224–1231. doi: https://doi.org/10.1016/j.fertnstert.2013.08.041.
- Friedler, S., Koc, O., Gidoni, Y., Raziel, A., & Ron-El, R. (2012). Ovarian response to stimulation for fertility preservation in women with malignant disease: a systematic review and meta-analysis. Fertility and Sterility, 97, 125–133. doi: https://doi.org/10.1016/j.fertnstert.2011.10.014.
- Goldman, K.N., Noyes, N.L., Knopman, J.M., McCaffrey, C., & Grifo, J.A. (2013). Oocyte efficiency: does live birth rate differ when analyzing cryopreserved and fresh oocytes on a per-oocyte basis? Fertility and Sterility, 100, 712–717. doi: https://doi.org/10.1016/j.fertnstert.2013.04.040.
- Griesinger, G., Mannaerts, B., Andersen, C.Y., Witjes, H., Kolibianakis, E.M., & Gordon, K. (2013). Progesterone elevation does not compromise pregnancy rates in high responders: a pooled analysis of in vitro fertilization patients treated with recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in six trials. Fertility and Sterility, 100, 1622–1628.e1-3. doi: https://doi.org/10.1016/j.fertnstert.2013.08.045.
- Hackeloer, B.J., Fleming, R., Robinson, H.P., Adam, A.H., & Coutts, J.R. (1979). Correlation of ultrasonic and endocrinologic assessment of human follicular development. American Journal of Obstetrics and Gynecology, 135, 122–128. Retrieved from: https://doi.org/https://www.ncbi.nlm.nih.gov/pubmed/474642.
- Hamdine, O., Macklon, N.S., Eijkemans, M.J., Laven, J.S., Cohlen, B.J., Verhoeff, A., … Broekmans, F.J. (2014). Elevated early follicular progesterone levels and in vitro fertilization outcomes: a prospective intervention study and meta-analysis. Fertility and Sterility, 102, 448–454.e1. doi: https://doi.org/10.1016/j.fertnstert.2014.05.002.
- Howlader, N., Noone, A.M., Yu, M., & Cronin, K.A. (2012). Use of imputed population-based cancer registry data as a method of accounting for missing information: application to estrogen receptor status for breast cancer. American Journal of Epidemiology, 176, 347–356. doi: https://doi.org/10.1093/aje/kwr512.
- Kasum, M., Von Wolff, M., Franulic, D., Cehic, E., Klepac-Pulanic, T., Oreskovic, S., & Juras, J. (2015). Fertility preservation options in breast cancer patients. Gynecological Endocrinology, 31, 846–851. doi: https://doi.org/10.3109/09513590.2015.1081684.
- Kuang, Y., Chen, Q., Hong, Q., Lyu, Q., Ai, A., Fu, Y., & Shoham, Z. (2014a). Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reproductive Biomedicine Online, 29, 684–691. doi: https://doi.org/10.1016/j.rbmo.2014.08.009.
- Kuang, Y., Hong, Q., Chen, Q., Lyu, Q., Ai, A., Fu, Y., & Shoham, Z. (2014b). Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. Fertility and Sterility, 101, 105–111. doi: https://doi.org/10.1016/j.fertnstert.2013.09.007.
- Letourneau, J.M., Ebbel, E.E., Katz, P.P., Oktay, K.H., McCulloch, C.E., Ai, W.Z., … Rosen, M.P. (2012). Acute ovarian failure underestimates age-specific reproductive impairment for young women undergoing chemotherapy for cancer. Cancer, 118, 1933–1939. doi: https://doi.org/10.1002/cncr.26403.
- Mathur, R.S., & Tan, B.K. (2014). British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome. Human Fertility, 17, 257–268. doi: https://doi.org/10.3109/14647273.2014.961745.
- McLaren, E. (2013). Live births in England and Wales by characteristics of mother 1, 2011. Office For National Statistics. Retrieved from http://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/livebirths/bulletins/livebirthsinenglandandwalesbycharacteristicsofmother1/2015-01-24.
- Moulin, J., Marszalek, A., Gayet, V., Blanchet, V., Streuli, I., Lafay, M., … De Ziegler, D. (2011). In donor-egg IVF, coh outcome is not affected when progestin-delivering iuds (mirenaÆ) or implants (implanonÆ) are left in place. Human Reproduction, 26(Suppl. 1), i50–i53. doi: https://doi.org/10.1093/humrep/26.s1.35.
- National Collaborating Centre for Women’s and Children’s Health. (2013). Fertility: assessment and treatment for people with fertility problems. London, UK. National Institute for Health and Clinical Excellence (NICE); 2013 Feb. 63 p. Clinical Guideline No. 156. Retrieved from https://www.guideline.gov/summaries/summary/43841.
- Noyes, N., Porcu, E., & Borini, A. (2009). Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reproductive Biomedicine Online, 18, 769–776. doi: https://doi.org/10.1016/S1472-6483(10)60025-9.
- Patrizio, P., & Sakkas, D. (2009). From oocyte to baby: a clinical evaluation of the biological efficiency of in vitro fertilization. Fertility and Sterility, 91, 1061–1066. doi: https://doi.org/10.1016/j.fertnstert.2008.01.003.
- Pinto, E., Pinelo, S., Osorio, M., Ferreira, C., Serra, H., Pires, I., … Tavares, A. (2012). Outcomes from ovarian hyperstimulation following the sole administration of gonadotrophin-releasing hormone agonist in the context of in vitro fertilization: report of two cases and review of the literature. Gynecological Endocrinology, 28, 545–548. doi: https://doi.org/10.3109/09513590.2011.650745.
- Reddy, J., & Oktay, K. (2012). Ovarian stimulation and fertility preservation with the use of aromatase inhibitors in women with breast cancer. Fertility and Sterility, 98, 1363–1369. doi: https://doi.org/10.1016/j.fertnstert.2012.09.022.
- Rodriguez-Wallberg, K.A., & Oktay, K. (2012). Options on fertility preservation in female cancer patients. Cancer Treatment Reviews, 38, 354–361. doi: https://doi.org/10.1016/j.ctrv.2011.10.002.
- Sönmezer, M., Turkcuoglu, I., Coskun, U., & Oktay, K. (2011). Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertility and Sterility, 95, 2125.e9–2111. doi: https://doi.org/10.1016/j.fertnstert.2011.01.030.
- The Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. (2013). Mature oocyte cryopreservation: a guideline fertility and sterility. Fertility and Sterility, 99, 37–43. doi: https://doi.org/10.1016/j.fertnstert.2012.09.028.
- Vlahos, N.F., Choussein, S., & Economopoulos, K.P. (2009). Follicular development, acquisition of mature oocytes, and pregnancy after 2 weeks of leuprolide acetate administration during the midluteal phase. Fertility and Sterility, 92, 1170 e9–1e11. doi: https://doi.org/10.1016/j.fertnstert.2009.05.067.
- Von Wolff, M., Capp, E., Jauckus, J., Strowitzki, T., Germeyer, A., on behalf of the FertiPROTEKT study group. (2016). Timing of ovarian stimulation in patients prior to gonadotoxic therapy: an analysis of 684 stimulations. European Journal of Obstetrics, Gynecology and Reprodoctive Biology, 199, 146–149. doi: https://doi.org/10.1016/j.ejogrb.2016.02.006.
- Weissman, A., Barash, A., Shapiro, H., & Casper, R.F. (1998). Ovarian hyperstimulation following the sole administration of agonistic analogues of gonadotrophin releasing hormone. Human Reproduction, 13, 3421–3424. doi: https://doi.org/10.1093/humrep/13.12.3421.
- Youssef, M.A., Abdelmoty, H.I., Ahmed, M.A., & Elmohamady, M. (2015). GnRH agonist for final oocyte maturation in GnRH antagonist co-treated IVF/ICSI treatment cycles: systematic review and meta-analysis. Journal of Advanced Research, 6, 341–349. doi: https://doi.org/10.1016/j.jare.2015.01.005.